Concurrent Schistosoma mansoni infection suppresses induction of HIV-1 Env-specific antibodies in a DNA-MVA-gp140 Env vaccine regimen in rhesus macaques

(Sm) infection. The vaccine expressed HIV Env derived from HIV-1 CAP256SU and a mosaic HIV-1 gag gene. Sm-free RMs received sequential DNA, MVA and gp140 Env protein immunizations, while a separate group was infected with Sm prior to receiving the same regimen. Sm-infection was confirmed using parasitological and serological assays. HIV-1 gp140 Env-specific binding antibodies (bAb) and neutralizing antibodies (nAb) against MW965.26, 6644, Consensus C, and CAP256SU pseudoviruses, and IFN-γ ELISpot responses were longitudinally evaluated. Both vaccinated Sm-free and Sm-infected RMs developed robust bAb and moderate nAb responses to MW965.26 after MVA immunization, which were maintained following protein boosts. However, these antibody responses were significantly reduced in Sm-infected animals. A subset of animals showed modest nAb activity against 6644 and Consensus C, with no consistently detectable neutralization of CAP256SU. Vaccinated Sm-free RMs developed low to moderate IFN-γ ELISpot responses that increased after MVA boosting. Sm-free vaccinated animals were subsequently challenged intrarectally with SHIV-CAP256SU. Before this, SHIV CAP256 replication was confirmed in intravenously challenged RMs. Seven of eight vaccinated animals became viremic, with peak viral loads comparable to controls. While survival rates did not differ significantly, vaccinated RMs demonstrated a lower hazard risk. Overall, this vaccine regimen elicited functional humoral and cellular immune responses, while concurrent Sm-infection significantly suppressed HIV-1 antibody induction.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2026-11-18
DOI
https://doi.org/10.1080/21645515.2026.2764010
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Concurrent Schistosoma mansoni infection suppresses induction of HIV-1 Env-specific antibodies in a DNA-MVA-gp140 Env vaccine regimen in rhesus macaques

Asisipho Mzukwa, Anna‐Lise Williamson, Qiniso Mkhize, Nicola Douglass et al.
Human Vaccines & Immunotherapeutics
HIV Research and Treatment
article

Concurrent Schistosoma mansoni infection suppresses induction of HIV-1 Env-specific antibodies in a DNA-MVA-gp140 Env vaccine regimen in rhesus macaques

Asisipho Mzukwa, Anna‐Lise Williamson, Qiniso Mkhize, Nicola Douglass, Rosamund E. Chapman, Gerald K. Chege, Nonkululeko B. Mzindle, Craig H. Adams, Alana T. Keyser, Michiel T. van Diepen, Penny L. Moore
article en

Abstract

(Sm) infection. The vaccine expressed HIV Env derived from HIV-1 CAP256SU and a mosaic HIV-1 gag gene. Sm-free RMs received sequential DNA, MVA and gp140 Env protein immunizations, while a separate group was infected with Sm prior to receiving the same regimen. Sm-infection was confirmed using parasitological and serological assays. HIV-1 gp140 Env-specific binding antibodies (bAb) and neutralizing antibodies (nAb) against MW965.26, 6644, Consensus C, and CAP256SU pseudoviruses, and IFN-γ ELISpot responses were longitudinally evaluated. Both vaccinated Sm-free and Sm-infected RMs developed robust bAb and moderate nAb responses to MW965.26 after MVA immunization, which were maintained following protein boosts. However, these antibody responses were significantly reduced in Sm-infected animals. A subset of animals showed modest nAb activity against 6644 and Consensus C, with no consistently detectable neutralization of CAP256SU. Vaccinated Sm-free RMs developed low to moderate IFN-γ ELISpot responses that increased after MVA boosting. Sm-free vaccinated animals were subsequently challenged intrarectally with SHIV-CAP256SU. Before this, SHIV CAP256 replication was confirmed in intravenously challenged RMs. Seven of eight vaccinated animals became viremic, with peak viral loads comparable to controls. While survival rates did not differ significantly, vaccinated RMs demonstrated a lower hazard risk. Overall, this vaccine regimen elicited functional humoral and cellular immune responses, while concurrent Sm-infection significantly suppressed HIV-1 antibody induction.

Human Vaccines & ImmunotherapeuticsVol. 22(1)
National Health Laboratory Service (ZA), South African Medical Research Council (ZA), University of Cape Town (ZA), University of the Witwatersrand (ZA), University of KwaZulu-Natal (ZA)
University of Pennsylvania, Harvard University, Department of Science and Innovation, South Africa, National Research Foundation, South African Medical Research Council, Poliomyelitis Research Foundation, University of Cape Town, National Institutes of Health
Good health and well-being
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon